The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Pharmacological modification of retinal and visual function and relation to control of refractive error. Myopia (short-sightedness) affects many hundreds of millions of people worldwide and can lead to blindness. Drug treatments that prevent myopia are being developed, however there is no efficient way of determining who is at risk of myopia or who will benefit from these treatments. This fundamental research project will determine the retinal and visual effects of pharmacologic agents that inhi ....Pharmacological modification of retinal and visual function and relation to control of refractive error. Myopia (short-sightedness) affects many hundreds of millions of people worldwide and can lead to blindness. Drug treatments that prevent myopia are being developed, however there is no efficient way of determining who is at risk of myopia or who will benefit from these treatments. This fundamental research project will determine the retinal and visual effects of pharmacologic agents that inhibit myopia, with the aim of determining an ocular measure that is related to myopia, which is altered by drugs that are known to slow myopia progression, and that could be used as an indication of an agent's likely effectiveness.Read moreRead less
Controlling the spatial distribution of targeting ligands on dendrimer surfaces as a means of dictating cellular recognition and fate. This project seeks to develop next generation targeted drug delivery systems that 'home' to specific target cells, including cancers. Targeted delivery systems have the potential to revolutionise therapy by providing bespoke drug distribution patterns that are tailored to specific diseases and result in enhanced activity and reduced toxicity.
A VAST potential for ion channel drug discovery. The purpose of this project is to bring innovation into the methods used for identifying and characterising novel carbohydrate-based compounds acting at ion channels. These molecules will have high potential to be developed as highly effective treatments for pain without the unpleasant side-effects associated with current treatments.
Engineering of composite particles to enhance performance in respiratory drug delivery. Respiratory conditions such as asthma and chronic pulmonary disease affect in excess of 5.8 million Australians and the common method of treatment is via drug inhalation. Although a wide range of drugs are commercially available as dry powder inhalers the efficiency of these systems is poor, with most devices delivering less than 20% to the lung. This project will develop a new method of high-efficiency respi ....Engineering of composite particles to enhance performance in respiratory drug delivery. Respiratory conditions such as asthma and chronic pulmonary disease affect in excess of 5.8 million Australians and the common method of treatment is via drug inhalation. Although a wide range of drugs are commercially available as dry powder inhalers the efficiency of these systems is poor, with most devices delivering less than 20% to the lung. This project will develop a new method of high-efficiency respiratory drug delivery based on composite particles. The technology developed from this project will advance Australia’s Research & Innovation and Pharmaceutical industry sector, and improve healthcare outcomes in the government’s key priority area of Promoting and maintaining good health: ‘A healthy start to life’ and ‘Ageing well’Read moreRead less
Perturbation of the extracellular architecture to promote the absorption and lymphatic transport of biological macromolecules. Macromolecules therapeutics such as proteins, antibodies or polymer conjugates pose a number of pharmaceutical challenges. Where the dose is high, drainage of that dose from a subcutaneous injection site into the circulation, poses a particular problem. Here the project aims to explore how recombinant hyaluronidase, an enzyme that breaks down a structural component (hya ....Perturbation of the extracellular architecture to promote the absorption and lymphatic transport of biological macromolecules. Macromolecules therapeutics such as proteins, antibodies or polymer conjugates pose a number of pharmaceutical challenges. Where the dose is high, drainage of that dose from a subcutaneous injection site into the circulation, poses a particular problem. Here the project aims to explore how recombinant hyaluronidase, an enzyme that breaks down a structural component (hyaluronan) of the interstitum, can be used promote absorption into the draining blood and lymph capillaries. The project aims to also explore the downstream effects of hyaluronidase on lymph nodes and evaluate whether the enzyme is able to temporarily disrupt the lymph node structure and promote drug penetration into the lymph node mass. This has significant potential for improved drug targeting.Read moreRead less
Therapeutic approaches to treat human immunodeficiency virus infection: development of HIV-1 integrase inhibitors. This project aims to assist the development of new anti-HIV drugs, which would benefit the 15000 Australians and over 40 million people worldwide who are currently infected with this terrible disease. The project will utilise state of the art technologies - including the Australian Synchrotron when it is commissioned in 2007 - to identify and synthesise compounds as new leads for th ....Therapeutic approaches to treat human immunodeficiency virus infection: development of HIV-1 integrase inhibitors. This project aims to assist the development of new anti-HIV drugs, which would benefit the 15000 Australians and over 40 million people worldwide who are currently infected with this terrible disease. The project will utilise state of the art technologies - including the Australian Synchrotron when it is commissioned in 2007 - to identify and synthesise compounds as new leads for the treatment of HIV.Read moreRead less
Refinement And Delivery Of Synthetic Compounds That Specifically Alter Muscle Contraction. The project has broad benefits for the nation and the community. Cutting edge research at the molecular level, done within Australia, will benefit Australian scientists and research in general. The discovery of drugs that will be developed by the Australian Pharmaceutical Industry will benefit the Australian Industry sector and will have spin-offs for the racing industry, livestock industry (lean meat) an ....Refinement And Delivery Of Synthetic Compounds That Specifically Alter Muscle Contraction. The project has broad benefits for the nation and the community. Cutting edge research at the molecular level, done within Australia, will benefit Australian scientists and research in general. The discovery of drugs that will be developed by the Australian Pharmaceutical Industry will benefit the Australian Industry sector and will have spin-offs for the racing industry, livestock industry (lean meat) and for rural industry (insecticides). In addition, expansion of the outcomes of the project into preclinical development will strengthen the Australian bioscience sector. Thus the project will eventually benefit the Australian industry sector. The project will have further benefits for education and training. Read moreRead less
Targeted development of dual action antitumour and antiangiogenic agents using differential and functional proteomics. There is an enormous need to develop more effective and less toxic therapeutic approaches to reduce the social and economic burden of cancer. The recent identification of small molecules that can act by both destroying cancer cells and the blood vessels that carry nutrients to them has provided a unique opportunity to define the pathways involved in the action of these agents in ....Targeted development of dual action antitumour and antiangiogenic agents using differential and functional proteomics. There is an enormous need to develop more effective and less toxic therapeutic approaches to reduce the social and economic burden of cancer. The recent identification of small molecules that can act by both destroying cancer cells and the blood vessels that carry nutrients to them has provided a unique opportunity to define the pathways involved in the action of these agents in order to develop more potent drug analogues. Development of these molecules will involve a collaborative and multidisciplinary link with our industry partner and the use of frontier technologies that may lead to improved health and economic outcomes for Australia. Read moreRead less
DsbA: A target for the design of drug candidates as selective inhibitors of oxidative protein folding in Gram negative bacteria. There is a clear need for development of novel antibiotics which are capable of treating the increasingly prevalent strains of pathogenic bacteria that are resistant to currently available drugs. In this proposal we will design novel inhibitors of bacterial enzymes that are required for the correct folding of a variety of proteins and test the effects of these molecule ....DsbA: A target for the design of drug candidates as selective inhibitors of oxidative protein folding in Gram negative bacteria. There is a clear need for development of novel antibiotics which are capable of treating the increasingly prevalent strains of pathogenic bacteria that are resistant to currently available drugs. In this proposal we will design novel inhibitors of bacterial enzymes that are required for the correct folding of a variety of proteins and test the effects of these molecules on enzyme activity, bacterial growth and antibiotic resistance. Specific inhibitors of these enzymes constitute a novel strategy for the treatment of bacteria that have developed resistance to existing antimicrobial drugs.
Read moreRead less
Supersaturated and non-digestible dispersions in the intestinal lumen: new mechanisms to reduce variability in the rate and extent of drug absorption. This project will design new polymers to be included in capsule formulations to prevent the precipitation of drugs in the intestine after their oral administration. This new technology will reduce the incidence of side-effects and ensure that patients absorb the correct dose of drug regardless of whether they take the drug before or after food.